Data from: Complex antiarrhythmic effects of empagliflozin in non-ischemic HFrEF cardiomyocytes
Abstract
This dataset contains the source data supporting the article entitled Complex antiarrhythmic effects of empagliflozin in non-ischemic HFrEF cardiomyocytes. This dataset supports key findings about the cardiac electrophysiological effects of empagliflozin in established non-diabetic, non-ischemic chronic heart failure with reduced ejection fraction (HFrEF) models in rabbits (combined volume and pressure overload) and mice (transverse aortic constriction, TAC). Electrophysiology data, including action potentials and ionic currents, are included in separate Excel sheets with individual cell data and group statistics. The dataset is structured to follow the sequence of data presented in the Figures in the article and to ease navigation between the uploaded data files.
How strong is the evidence?
Evidence Hub reads this as a dataset, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.